Ascendis Pharma (ASND) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $15.80B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | DK | CEO | Jan Moller Mikkelsen |
| IPO Date | 2015-01-28 | CAGR | 33.88% |
| Employees | 1,017 | Website | ascendispharma.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.09% | Total Yield | 0.09% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $13.07B | P/E | -105.14 | Forward P/E | 27.4 | PEG | — |
| P/S | 66.39 | P/B | 117.67 | P/CF | 997.03 | P/FCF | 1366.92 |
| Sales | $1.01B | Sales 1Y | 135.29% | Sales 3Y | 1013.13% | Sales 5Y | 15747.91% |
| EPS | $-2.42 | EPS 1Y | — | EPS 3Y | — | EPS 5Y | — |
| Sales QoQ | 2.23% | EPS QoQ | -1935.19% | Sales QoQ Avg | 27.18% | EPS QoQ Avg | -501.83% |
| Gross Margin | 88.17% | Operating Margin | -0.8% | Profit Margin | 58.4% | ROCE | -0.79% |
| ROA | 25% | ROE | -5642% | Altman Z Score | 4.35 | Piotroski Score | 5 |
| Current Ratio | 1 | Quick Ratio | 0.72 | Cash Ratio | 0.51 | Op. CF Ratio | -0.01 |
| Debt/Equity | 1.84 | Debt/Assets | 0.45 | Lt Debt/Equity | 0.79 | Lt Debt/Cap. | 0.44 |
| Intrst Cov. | -0.04 | Inventory Turnover | 0.33 | Asset Turnover | 0.43 | Receivables Turnover | 4.41 |
| Enterprise Value | $13.07B | P/E Ratio | -105.14 |
| Forward P/E | 27.4 | PEG Ratio | — |
| P/S Ratio | 66.39 | P/B Ratio | 117.67 |
| P/CF Ratio | 997.03 | P/FCF Ratio | 1366.92 |
| EPS | $-2.42 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 135.29% | Gross Margin | 0.88% |
| Operating Margin | -0.01% | Profit Margin | 0.58% |
| ROE | -56.42% | ROA | 0.25% |
| ROCE | -0.01% | Current Ratio | 1 |
| Quick Ratio | 0.72 | Cash Ratio | 0.51 |
| Debt/Equity | 1.84 | Interest Coverage | -0.04 |
| Altman Z Score | 4.35 | Piotroski Score | 5 |
Ascendis Pharma (ASND) valuation & financials
Ascendis Pharma (ASND) has a market capitalization of $15.80B and trades at a price-to-earnings ratio of -105.1. It operates in the Healthcare sector (Biotechnology).
Ascendis Pharma's revenue grew +135.3% over the last year.
Ascendis Pharma's next earnings report is scheduled for August 6, 2026; analysts estimate EPS of $1.27.
Ascendis Pharma (ASND) — frequently asked questions
When does Ascendis Pharma (ASND) report earnings next?
Ascendis Pharma is expected to report earnings on August 6, 2026. Analysts estimate EPS of $1.27.
What is Ascendis Pharma's market cap?
Ascendis Pharma (ASND) has a market capitalization of $15.80B.
What is ASND's P/E ratio?
Ascendis Pharma trades at a price-to-earnings ratio of -105.1, with trailing twelve-month EPS of $-2.42.
How fast is Ascendis Pharma growing?
Ascendis Pharma's revenue grew +135.3% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)